FDA Approves Xolair (Omalizumab) for Reducing Severe Outcomes from Multiple Food Allergies
Xolair, United States Food and Drug Administration, omalizumab, Hypersensitivity, Food, Reduced, Severe (severity modifier)
Daiichi Sankyo Invests $1 Billion to Expand German Facility for Precision Cancer Antibody-Drug Conjugates
Daiichi, Sankyo, Antibody-Drug Conjugates
Sanofi and Denali’s ALS Candidate SAR443820 Fails Phase 2 Trial
Amyotrophic Lateral Sclerosis, sanofi, SAR443820, Denali, Collaboration, Denali’s
FDA Approves Amtagvi as the First One-time Cell Therapy for Solid Tumors: A Groundbreaking TIL Immunotherapy for Advanced Melanoma
Amtagvi, Solid Neoplasm, United States Food and Drug Administration, Lymphocytes, Tumor-Infiltrating
Alvotech and Teva Settle with Johnson & Johnson for Stelara Biosimilar AVT04 in the US
Alvotech, Teva, Settlement and Resettlement, AVT04, United States
Inventiva Halts Enrollment in Phase 3 MASH Study Following Patient Raised Liver Enzyme Incident
Clinical Research, lanifibranor, Incident
Revolutionary Protein Degraders Integrated into Antibody-Drug Conjugates: Carolyn Bertozzi and Versant Launch New Biotech with $94 Million Funding
Carolyn Bertozzi, Versant Ventures, Firefly Bio, Protein degraders, Antibody-drug conjugates (ADCs), Degrader-Antibody Conjugates (DACs), $94 million funding